Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A slowly progressive autoimmune demyelinating disease of peripheral nerves and nerve roots. Clinical manifestations include weakness and sensory loss in the extremities and enlargement of peripheral nerves. The course may be relapsing-remitting or demonstrate a step-wise progression. Protein is usually elevated in the spinal fluid and cranial nerves are typically spared. GUILLAIN-BARRE SYNDROME features a relatively rapid progression of disease which distinguishes it from this condition. (Adams et al., Principles of Neurology, 6th ed, p1337)
| Descriptor ID |
D020277
|
| MeSH Number(s) |
C10.114.750.175 C10.314.750.700 C10.668.829.800.750.600 C20.111.258.750.800
|
| Concept/Terms |
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- CIDP
- Polyneuropathy, Inflammatory Demyelinating, Chronic
- Inflammatory Polyradiculopathy, Chronic
- Chronic Inflammatory Polyradiculopathies
- Chronic Inflammatory Polyradiculopathy
- Inflammatory Polyradiculopathies, Chronic
- Polyradiculopathies, Chronic Inflammatory
- Polyradiculopathy, Chronic Inflammatory
- Polyradiculoneuropathy, Chronic Inflammatory
- Chronic Inflammatory Polyradiculoneuropathy
- Chronic Inflammatory Polyradiculoneuropathies
- Polyradiculoneuropathies, Chronic Inflammatory
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
|
Below are MeSH descriptors whose meaning is more general than "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating".
Below are MeSH descriptors whose meaning is more specific than "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating".
This graph shows the total number of publications written about "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating" by people in this website by year, and whether "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 3 | 0 | 3 |
| 2003 | 2 | 0 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 1 | 3 |
| 2010 | 4 | 0 | 4 |
| 2011 | 4 | 0 | 4 |
| 2012 | 2 | 0 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2022 | 2 | 0 | 2 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating" by people in Profiles.
-
Dalakas MC, Latov N, Kuitwaard K. Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): mechanisms of action and clinical and genetic considerations. Expert Rev Neurother. 2022 Nov-Dec; 22(11-12):953-962.
-
Querol LA, Hartung HP, Lewis RA, van Doorn PA, Hammond TR, Atassi N, Alonso-Alonso M, Dalakas MC. The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies. Neurotherapeutics. 2022 04; 19(3):864-873.
-
Dalakas MC. Autoimmune Neurological Disorders with IgG4 Antibodies: a Distinct Disease Spectrum with Unique IgG4 Functions Responding to Anti-B Cell Therapies. Neurotherapeutics. 2022 04; 19(3):741-752.
-
Keller CW, Quast I, Dalakas MC, L?nemann JD. IVIG efficacy in CIDP patients is not associated with terminal complement inhibition. J Neuroimmunol. 2019 05 15; 330:23-27.
-
Hughes R, Dalakas MC, Merkies I, Latov N, L?ger JM, Nobile-Orazio E, Sobue G, Genge A, Cornblath D, Merschhemke M, Ervin CM, Agoropoulou C, Hartung HP. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. Lancet Neurol. 2018 08; 17(8):689-698.
-
Dalakas MC. Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy. Lancet Neurol. 2018 01; 17(1):20-21.
-
Dalakas MC, Gooch C. Close to the node but far enough: What nodal antibodies tell us about CIDP and its therapies. Neurology. 2016 Mar 01; 86(9):796-7.
-
Quast I, Keller CW, Maurer MA, Giddens JP, Tackenberg B, Wang LX, M?nz C, Nimmerjahn F, Dalakas MC, L?nemann JD. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity. J Clin Invest. 2015 Nov 02; 125(11):4160-70.
-
Chin RL, Deng C, Bril V, Hartung HP, Merkies IS, Donofrio PD, Van Doorn PA, Dalakas MC, Latov N. Follow-up nerve conduction studies in CIDP after treatment with IGIV-C: Comparison of patients with and without subsequent relapse. Muscle Nerve. 2015 Oct; 52(4):498-502.
-
Dalakas MC. Pathogenesis of immune-mediated neuropathies. Biochim Biophys Acta. 2015 Apr; 1852(4):658-66.